Lipoprotein particle subclasses, cardiovascular disease and HIV infection. - Test2 - elhamkhani - TriplyDB

Lipoprotein particle subclasses, cardiovascular disease and HIV infection.

Lipoprotein particle subclasses, cardiovascular disease and HIV infection.

http://www.wikidata.org/entity/Q33639078

about

HIV infection and cardiovascular disease Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010 Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?Cardiovascular Complications of HIV Infection.High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection.Low HDL-cholesterol among HIV-1 infected and HIV-1 uninfected individuals in Nairobi, Kenya.Residual immune dysregulation syndrome in treated HIV infection.Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy.Mutation of the ATP cassette binding transporter A1 (ABCA1) C-terminus disrupts HIV-1 Nef binding but does not block the Nef enhancement of ABCA1 protein degradation.Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection.Biomarkers and HIV-associated cardiovascular disease.HIV, HAART, and lipoprotein particle concentrations in the Women's Interagency HIV Study.Biomarkers of immune dysfunction in HIV.HIV/hepatitis C virus coinfection ameliorates the atherogenic lipoprotein abnormalities of HIV infection Plasma levels of soluble CD14 independently predict mortality in HIV infection.Cardiovascular implications from untreated human immunodeficiency virus infection.Cardiac effects of in-utero exposure to antiretroviral therapy in HIV-uninfected children born to HIV-infected mothers The CD14 C-260T single nucleotide polymorphism (SNP) modulates monocyte/macrophage activation in treated HIV-infected individuals.Characterization of lipid composition and high-density lipoprotein function in HIV-infected individuals on stable antiretroviral regimens.Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy.Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAART Reduced IgM levels and elevated IgG levels against oxidized low-density lipoproteins in HIV-1 infection.Dyslipidemia and lipid management in HIV-infected patients Lipoprotein concentration, particle number, size and cholesterol efflux capacity are associated with mitochondrial oxidative stress and function in an HIV positive cohort.HDL redox activity is increased in HIV-infected men in association with macrophage activation and non-calcified coronary atherosclerotic plaque.Correlation between HIV disease and lipid metabolism in antiretroviral-naïve HIV-infected patients in Japan.Lipid levels in HIV-positive men receiving anti-retroviral therapy are not associated with copy number variation of reverse cholesterol transport pathway genes.Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy.Incident hypertension in older women and men with or at risk for HIV infection.Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation.Gut Mucosal Barrier Dysfunction, Microbial Dysbiosis, and Their Role in HIV-1 Disease Progression.High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis).High-Density Lipoprotein Subclasses and Noncardiovascular, Noncancer Chronic Inflammatory-Related Events Versus Cardiovascular Events: The Multi-Ethnic Study of Atherosclerosis.Vitamin D Levels and Markers of Inflammation and Metabolism in HIV-Infected Individuals on Suppressive Antiretroviral Therapy Cardiometabolic risk factors among HIV patients on antiretroviral therapy.Current understanding of HIV-associated neurocognitive disorders pathogenesis.Genetic polymorphisms in the CD14 gene are associated with monocyte activation and carotid intima-media thickness in HIV-infected patients on antiretroviral therapy.Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection.The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study.Microbial translocation and metabolic and body composition measures in treated and untreated HIV infection

P2860

Q27008915-5116A3E7-B965-4407-891C-AAA81A794340 Q27690715-A3528809-F7F9-496F-917A-EABC557C964B Q28086787-EE2A84FD-25B5-4EEB-83B9-2035570E96E0 Q30235920-399A2220-3FE8-414B-83F9-6558BBB1A607 Q33556997-441B757E-7422-45B7-B1E8-70BBA0BA7BFA Q33785181-0C6593D4-0BCA-4DC7-863D-F4695CB79EBA Q34020121-E5ECFBF1-90B3-48AF-97A8-18A90BDB8823 Q34079197-5BB7382C-2DE1-4E63-8605-767022D25C2D Q34146122-4F7BEF9B-BEF2-4773-B92A-0E1BA4F70904 Q34315572-881D8EAD-C8A6-4358-8E89-23E5E67E4C1C Q34335486-803C1814-B2F4-4CF6-A343-A1DDD7F924D7 Q34355660-3C14C352-28EE-40AD-941F-9E62A4878DEF Q34546742-71C2BD80-2578-4CEC-8E36-D3E6C98B32B0 Q34712485-43AE9CEF-662E-43C3-AE97-4E1B9C33C683 Q34764002-5E766523-6CF6-44F1-A056-227CC0514071 Q34793193-5027C9BE-09B0-4BB8-8352-CCBE098684EB Q34881120-8F9F0EC1-8B03-4D4E-BB19-F20F49F01EEE Q35030351-4F1D6FAD-2955-4FA0-B50E-2F3511B3F9A5 Q35036648-6489DF35-0400-45DD-8A4B-34C10FF42C52 Q35051199-671390C2-20F5-4B1C-8379-BC4247845161 Q35120957-EFDF1CE8-D3F4-4D7F-93BA-B4E44508787D Q35122438-A02DBA59-C754-4B6A-B4BE-3ACAE1A66922 Q35160574-82BA72F6-9495-4B0D-90EA-79B7137107AE Q35209036-CCC10F52-64A4-44B2-A330-CD899E60FA1C Q35579905-E906B757-55D4-42FE-9BE0-A80CD4A1E7BF Q35754336-A2F29C41-48C7-4659-B0C0-E988FFF9364B Q35847854-04C5126C-FD10-42D3-B25C-9C7A291DA300 Q35873877-B4148301-511A-4ADC-899D-2A1D4EEF162C Q36067337-5D05ABF1-FA27-48E5-8B08-A07F490641BC Q36087108-17FF2A11-7120-4562-8413-F98913F05C50 Q36132003-FC3953D1-4925-4756-8465-34D6D842F319 Q36139932-44976C82-A56C-47EA-AA64-09B1D4199886 Q36141889-70293216-EE3E-44BF-A6B5-3B6C697AF5E2 Q36656763-9976E2C8-A846-4C51-9431-1A156A070C6F Q36808820-59392216-34B1-4B4C-90AE-9298B54F7A0D Q36932005-BEA4BC09-ADD1-4AEA-9A8D-42FC4573CF71 Q37165196-F7916870-1134-484B-96ED-FE1C2C877D31 Q37319195-3A095D6F-B433-44AD-AE7F-3AA554504A0B Q37355492-F174D298-BCBD-4257-9049-5E3F972DE105 Q37610700-A4CBE05E-9B8F-4443-B6B8-D2C02CFE9606

P2860

Lipoprotein particle subclasses, cardiovascular disease and HIV infection.

http://www.wikidata.org/entity/Q33639078

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Lipoprotein particle subclasses, cardiovascular disease and HIV infection.

@ast

Lipoprotein particle subclasses, cardiovascular disease and HIV infection.

@en

type

label

Lipoprotein particle subclasses, cardiovascular disease and HIV infection.

@ast

Lipoprotein particle subclasses, cardiovascular disease and HIV infection.

@en

prefLabel

Lipoprotein particle subclasses, cardiovascular disease and HIV infection.

@ast

Lipoprotein particle subclasses, cardiovascular disease and HIV infection.

@en

P1433

Q33639078-D7561531-4E49-4080-9B65-1C66808EA527

P1476

Q33639078-3E620769-DF31-4B27-9259-DCA5AAEF2C10

P2093

Q33639078-05103C8D-C34C-436E-BA0C-D710B9C9B623

Q33639078-21ACC9B1-907C-4ADC-9DCE-C47C07A78396

Q33639078-3136C99C-1E56-4A4D-8BD9-0D02678698DD

Q33639078-517C4FD7-3D7C-40F8-AF83-BA3EEED6EE5C

Q33639078-7125DBF6-DFDE-4FFA-B570-3240C52F09FF

Q33639078-8409EB13-02DC-414F-8CC9-24059291739E

Q33639078-9491C8CE-3E75-47B3-9C27-372514984638

Q33639078-9696A2A8-62B9-4E86-B205-3A2D6F5A70A9

Q33639078-9D9AEC33-903A-4E23-8B37-F3844583A77E

Q33639078-CD4A75B5-72DE-4FD2-9AE6-3F9572BE1146

P2860

Q33639078-04A49C9F-91F6-4F23-8F30-6F9972D05978

Q33639078-158D44A8-09F3-44D0-A9C5-8E2F22D2F485

Q33639078-1E024E5E-BD25-49D1-A51D-077D1345B483

Q33639078-30448247-C9A9-470D-9379-DD14029B2249

Q33639078-36BD730E-F198-42BE-B254-1892AD045E73

Q33639078-3BD7D4A2-D30B-4765-A2AD-897E55709E11

Q33639078-4D5541B0-0E0F-41E8-BD40-0598711E06FF

Q33639078-60C8DF6E-A01C-4C28-8BA1-B62F93A0366C

Q33639078-7CA76B41-CB7F-45C3-982D-31EB52382994

Q33639078-7E4BFB5C-3E10-4D8B-88ED-45D1F4396936

P304

Q33639078-F814403F-6F92-4F67-A11C-14BDCBE42DB6

P31

Q33639078-BA2E38A7-01EB-4EC2-86B6-E88C7AEEA93F

P356

Q33639078-05C20FEA-5552-4BDB-9A38-950B208A7E31

P433

Q33639078-7FA842C3-16D7-4C25-A75C-92F6334C57A7

P478

Q33639078-73274D39-FF29-4FDB-805B-F020424A982B

P50

Q33639078-7D35B98E-BDCB-431A-92E1-AD43B2637D3F

Q33639078-8AEC8B2C-1E98-4F84-A14F-C731A04706D7

P577

Q33639078-3DFEAFEE-B09D-43D1-84DF-120650F85D1D

P5875

Q33639078-C0B09929-FDB4-4147-8DF3-F0B2EEFB6306

P698

Q33639078-5A0DF1CF-7AF9-4BBC-BBBD-C1AD07595597

P921

Q33639078-028E3FB4-A48E-4CB9-87C6-956A835974D3

Q33639078-E3D70052-A45E-4115-A440-44B3D1EF0610

P932

Q33639078-5C16B81D-4008-4F8C-AF2A-187FC1BCE739

P356

J.ATHEROSCLEROSIS.2009.05.001

P1433

Atherosclerosis

P1476

Lipoprotein particle subclasses, cardiovascular disease and HIV infection

@en

P2093

Angelike P Liappis

http://www.w3.org/2001/XMLSchema#string

Daniel A Duprez

http://www.w3.org/2001/XMLSchema#string

David A Cooper

http://www.w3.org/2001/XMLSchema#string

Fiona Lampe

http://www.w3.org/2001/XMLSchema#string

INSIGHT SMART Study Group

http://www.w3.org/2001/XMLSchema#string

Jacqueline Neuhaus

http://www.w3.org/2001/XMLSchema#string

James D Neaton

http://www.w3.org/2001/XMLSchema#string

James Otvos

http://www.w3.org/2001/XMLSchema#string

Lewis H Kuller

http://www.w3.org/2001/XMLSchema#string

Nicholas I Paton

http://www.w3.org/2001/XMLSchema#string

P2860

Inflammatory and coagulation biomarkers and mortality in patients with HIV infection

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

CD4+ count-guided interruption of antiretroviral treatment

Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy.

Molecular regulation of HDL metabolism and function: implications for novel therapies.

Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors

Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome

HIV infection and high density lipoprotein metabolism

HIV-associated dyslipidaemia: pathogenesis and treatment.

Evidence of systemic inflammation and estimation of coronary artery disease risk: a population perspective.

P304

524-529

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.ATHEROSCLEROSIS.2009.05.001

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

207

http://www.w3.org/2001/XMLSchema#string

P50

Nina Friis-Moller

P577

2009-05-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26281575

http://www.w3.org/2001/XMLSchema#string

P698

19515371

http://www.w3.org/2001/XMLSchema#string

P921

cardiovascular disease

P932

2818719

http://www.w3.org/2001/XMLSchema#string